重度哮喘咳嗽频率与2型炎症标志物的观察性研究
该观察性研究纳入61例哮喘患者(42例重度、19例轻中度),评估客观咳嗽监测与2型(T2)生物标志物及哮喘控制指标的关系。结果显示重度哮喘24小时咳嗽计数和频率均显著高于轻中度哮喘,且T2-low重度哮喘患者咳嗽频率显著低于T2-intermediate和T2-high患者。提示咳嗽频率与T2嗜酸性炎症相关,治疗咳嗽的首要策略可能是充分抑制T2炎症。
要点
- 重度哮喘24小时咳嗽计数和频率显著高于轻中度哮喘。
- T2-low重度哮喘患者咳嗽频率显著低于T2-intermediate和T2-high患者。
- 哮喘咳嗽机制可能与潜在T2嗜酸性炎症有关,首要治疗是抑制T2炎症。
核心结论
- 在T2炎症生物标志物低的患者中,咳嗽频率未升高,提示哮喘咳嗽机制与潜在T2嗜酸性炎症相关。
- 治疗哮喘咳嗽的合理第一步可能是用现有疗法充分抑制T2炎症。
研究设计与样本
- 观察性研究,纳入61例哮喘患者,其中重度哮喘42例、轻中度哮喘19例。
- 患者完成经验证的哮喘和咳嗽相关测量工具(包括动态咳嗽监测)以及肺功能检查和T2生物标志物检测。
- 根据T2状态分类:T2-low为FENO<20 ppb且外周血嗜酸性粒细胞<150 cells·µL-1,T2-intermediate为FENO≥20 ppb或外周血嗜酸性粒细胞≥150 cells·µL-1,T2-high为FENO≥20 ppb且外周血嗜酸性粒细胞≥150 cells·µL-1。
主要发现
- 重度哮喘患者24小时总咳嗽计数几何均值±标准差为170.3±2.7,轻中度哮喘为60.8±4.1,差异有统计学意义(p=0.002)。
- 重度哮喘患者咳嗽频率几何均值±标准差为7.1±2.7 coughs·h-1,轻中度哮喘为2.5±4.1 coughs·h-1,差异有统计学意义(p=0.002)。
- T2-low重度哮喘患者24小时咳嗽频率显著低于T2-intermediate和T2-high患者。
关键数值与推荐
- T2-low定义为FENO<20 ppb且外周血嗜酸性粒细胞<150 cells·µL-1。
- T2-intermediate定义为FENO≥20 ppb或外周血嗜酸性粒细胞≥150 cells·µL-1。
- T2-high定义为FENO≥20 ppb且外周血嗜酸性粒细胞≥150 cells·µL-1。
临床怎么用
- 对哮喘咳嗽患者,应评估T2炎症生物标志物(FENO和外周血嗜酸性粒细胞)以指导治疗。
- 对于T2炎症标志物低的患者,咳嗽频率可能不高,治疗重点可能不同于T2-high患者。
- 充分抑制T2炎症可能是治疗哮喘咳嗽的首选策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The relationship between objectively measured cough and type 2 (T2) biomarkers and other measures of asthma control and severity is poorly understood. The objective of this study was to assess the relationship between objective and subjective cough measurement tools and clinical biomarkers of asthma. METHODS: Patients with severe asthma and mild-to-moderate asthma completed validated asthma and cough-related measurement tools (including ambulatory cough monitoring) and measurement of spirometry and T2 biomarkers (exhaled nitric oxide fraction (F ENO) and peripheral blood eosinophil count). Patients were classified according to T2 status based on T2-low (F ENO <20 ppb and peripheral blood eosinophils <150 cells·µL-1), T2-intermediate (F ENO ≥20 ppb or peripheral blood eosinophils ≥150 cells·µL-1) or T2-high (F ENO ≥20 ppb and peripheral blood eosinophils ≥150 cells·µL-1). RESULTS: 61 patients completed the study measurements (42 severe asthma and 19 mild-to-moderate asthma). Patients with severe asthma had higher rates of cough than those with mild-to-moderate asthma in terms of total 24-h cough counts (geometric mean±sd 170.3±2.7 versus 60.8±4.1; p=0.002) and cough frequency (geometric mean±sd 7.1±2.7 versus 2.5±4.1 coughs·h-1; p=0.002). T2-low patients with severe asthma had significantly lower 24-h cough frequency compared with T2-intermediate and T2-high patients. CONCLUSIONS: In patients with low biomarkers of T2 inflammation, cough frequency measurements were not elevated, suggesting that the mechanism for cough in asthma is underlying T2 eosinophilic inflammation and the logical first step for treating cough in asthma may be to achieve adequate suppression of T2 inflammation with currently available therapies.
引用
- Holmes J, McGarvey LPA, Birring SS, et al. An observational study to determine the relationship between cough frequency and markers of inflammation in severe asthma. Eur Respir J. 2022. PMID: 35777770. doi:10.1183/13993003.03205-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。